ライフサイエンスコーパス: glaucoma surgery

1 echnique to treat hypotony maculopathy after glaucoma surgery.

2 tients (7/14); 3 eyes of 2 patients required glaucoma surgery.

3 to postoperative hypotony in eyes with prior glaucoma surgery.

4 nt cataract extraction, and 5 eyes underwent glaucoma surgery.

5 Five patients required glaucoma surgery.

6 es (12 Roper-Hall grade III or IV) underwent glaucoma surgery.

7 in eyes with previous cataract and/or failed glaucoma surgery.

8 s with previous cataract and/or unsuccessful glaucoma surgery.

9 ssure spikes that may necessitate additional glaucoma surgery.

10 lished literature relating to nonpenetrating glaucoma surgery.

11 fter trabeculectomy or combined cataract and glaucoma surgery.

12 quire oil removal with or without concurrent glaucoma surgery.

13 plications, including retinal, cataract, and glaucoma surgery.

14 ell as innovative techniques in cataract and glaucoma surgery.

15 l as for performing concomitant cataract and glaucoma surgery.

16 have vastly improved the results of combined glaucoma surgery.

17 nant of the final intraocular pressure after glaucoma surgery.

18 Nineteen percent of the patients needed glaucoma surgery.

19 ed glaucoma who had previous cataract and/or glaucoma surgery.

20 despite additional medications or requiring glaucoma surgery.

21 ter 3 months, severe vision loss, or de novo glaucoma surgery.

22 liary space allowed concomitant cataract and glaucoma surgery.

23 Overall, 5 of 68 eyes (7%), required further glaucoma surgery.

24 =25 mm Hg; none required laser or incisional glaucoma surgery.

25 OP lowering medications and without need for glaucoma surgery.

26 anent and require chronic medical therapy or glaucoma surgery.

27 ons, and had a lower requirement for further glaucoma surgery.

28 ntiglaucoma medications without any previous glaucoma surgery.

29 and prognosis in conjunctival fibrosis after glaucoma surgery.

30 ical cohort of 100 000 patients who required glaucoma surgery.

31 en higher risk for elevated IOP and possibly glaucoma surgery.

32 No patients required glaucoma surgery.

33 of patients because of the need for further glaucoma surgery.

34 ed glaucoma who had previous cataract and/or glaucoma surgery.

35 visual acuity, complications, and additional glaucoma surgery.

36 cations) without complications or additional glaucoma surgery.

37 with or without medications, without further glaucoma surgery.

38 ss rates or change the complication rates of glaucoma surgery.

39 hthalmologists who do not perform incisional glaucoma surgery.

40 their assigned treatment and had additional glaucoma surgery.

41 ical challenges in patients with preexisting glaucoma surgeries.

42 rving superior bulbar conjunctiva for future glaucoma surgeries.

43 ar pressure and success of trabecular bypass glaucoma surgeries.

44 Six patients had undergone prior glaucoma surgeries.

45 g with 5FU: 20.0% vs 23.7%, P > .99; further glaucoma surgery: 0% vs 13.2%, P = .15).

46 2.54 [IQR 1-4], P < .0001; median number of glaucoma surgeries, 1.0 [IQR 1-2] vs 1.25 [IQR 0.5-2.0],

47 e after cataract extraction (18/36, 50%) and glaucoma surgery (11/36, 31%).

48 n cause was secondary glaucoma or related to glaucoma surgery (12/22 eyes, 55%).

49 etroprosthetic membrane formation, 21.6% for glaucoma surgery, 18.6% for retinal detachment, and 15.5

50 ined EVFW had a higher likelihood of further glaucoma surgery (36%).

51 ngs were after cataract surgery (9/16, 56%), glaucoma surgery (4/16, 25%), and trauma (2/16, 13%).

52 olled, masked-observer study, after modified glaucoma surgery, 48 rabbits were randomly allocated to

53 rating keratoplasty, particularly with prior glaucoma surgery (58% with prior glaucoma surgery and us

54 surgery (10 eyes), and combined cataract and glaucoma surgery (7 eyes).

55 20% of pre-existing glaucoma patients needed glaucoma surgery after a CRVO event, including 11.7% of

56 Two eyes (0.7%) required glaucoma surgery after DMEK.

57 hment has been reported after nonpenetrating glaucoma surgery, although less endothelial loss is indu

58 The adjusted rate ratio of glaucoma surgery among those who received 7 or more inje

59 Seventy-four cases of glaucoma surgery and 740 controls were identified, with

60 ostoperative agent to prevent scarring after glaucoma surgery and compared it with 5-fluorouracil (5-

61 model can be used to test key components of glaucoma surgery and implant design.

62 ed to determine success in recent studies of glaucoma surgery and makes recommendations about the mos

63 osis gene signature in the conjunctiva after glaucoma surgery and provides new insights into the mech

64 significant improvement in vision following glaucoma surgery and review the literature regarding thi

65 annually is associated with a higher risk of glaucoma surgery and that 4 to 6 injections per year sho

66 with prior glaucoma surgery (58% with prior glaucoma surgery and use of medications to lower intraoc

67 y managed glaucoma, type and number of prior glaucoma surgeries, and occurrence of a rejection episod

68 mber of antiglaucoma medications, history of glaucoma surgery, and employment status were recorded.

69 a lower failure rate, lower rate of de novo glaucoma surgery, and lower mean IOP on fewer medication

70 aocular pressure, thus preventing failure of glaucoma surgery, and may also act as a potential adjuva

71 eedling with 5-fluorouracil (5FU) or further glaucoma surgery, and the incidence of complications rel

72 odulators of the scarring response following glaucoma surgery are reviewed.

73 The incidence of incisional glaucoma surgery at month 36 was 4.8% in the low-dose gr

74 y, 42 patients were recruited at the time of glaucoma surgery at the Moorfields Eye Hospital from Sep

75 a better safety profile with nonpenetrating glaucoma surgery but higher long-term intraocular pressu

76 Antifibrotics are potent adjuncts to glaucoma surgery, but along with their beneficial use ar

77 ical determinant of the long-term success of glaucoma surgery, but no reliable biomarkers are current

78 Most glaucoma surgery can adversely affect the cornea.

79 Risk of glaucoma surgery compared with the number of intravitreo

80 Nonpenetrating glaucoma surgery continues to evolve.

81 vine, California, USA), a minimally invasive glaucoma surgery device, in refractory glaucoma.

82 age of ophthalmologists providing incisional glaucoma surgery dropped from 35% in 1995 to 19% in 2010

83 participants (67%) had previously undergone glaucoma surgery (fibrotic group) (mean [SD] age, 43.8 [

84 To determine the risk of glaucoma surgery following repeated intravitreous bevaci

85 en-angle glaucoma and no previous incisional glaucoma surgery from 9 glaucoma units were evaluated re

86 d preexisting glaucoma (G), and 46 had prior glaucoma surgery (GS).

87 Age of the patient and glaucoma surgery had an influence on corneal thickness.

88 ion of ophthalmologists providing incisional glaucoma surgery has declined significantly.

89 Glaucoma surgery has evolved over the past 30 years from

90 Performing cataract extraction prior to glaucoma surgery has numerous benefits.

91 ouracil and mitomycin C, in conjunction with glaucoma surgery has resulted in lower postoperative int

92 However, other corneal effects of glaucoma surgery have also been reported.

93 Outflow procedures for glaucoma surgery have remained popular in the last decad

94 light perception, requirement for additional glaucoma surgery, hypotony maculopathy, and serious comp

95 Prior incisional glaucoma surgery imparted a 3.15 times greater risk of r

96 ucoma, precluding the need for more invasive glaucoma surgery in >80% of patients at 1 year, thereby

97 sions and optic disc cupping, and no further glaucoma surgery (including needling) or loss of light p

98 Recent modifications in nonpenetrating glaucoma surgery, including the use of implants, augment

99 hthalmologists who do not perform incisional glaucoma surgery increased 19.3% annually (P < .0001), w

100 hthalmologists who do not perform incisional glaucoma surgery increased at average annual rates of 1.

101 luding prior penetrating keratoplasty, prior glaucoma surgery, iridocorneal endothelial syndrome, ani

102 ical outcomes were observed after additional glaucoma surgery, irrespective of initial randomized tre

103 Following CRVO, glaucoma surgery is necessary for pre-existing glaucoma

104 ns and enhancements, traditional penetrating glaucoma surgery is not without complications and is res

105 Nonpenetrating glaucoma surgery is popular in a number of countries bec

106 ression suggests critical ages where further glaucoma surgery is required at around 2 and 5 years of

107 s proven to be an alternative to traditional glaucoma surgery, lowering IOP relatively well.

108 undergoing cataract removal after successful glaucoma surgery maintained IOP control.

109 n eyes originally indicated for conventional glaucoma surgery, no secondary surgery was performed in

110 ticipants (33%) had not previously undergone glaucoma surgery (nonfibrotic group) (mean [SD] age, 47.

111 included trabeculectomy and non-penetrating glaucoma surgery (NPGS) with mitomycin-C.

112 itiation of ocular hypotensive medication or glaucoma surgery of any kind.

113 er among eyes that had undergone cataract or glaucoma surgery or both (n = 28; P = 0.0004).

114 Human AH was obtained at the time of either glaucoma surgery or cataract extraction.

115 r and posterior segments combined surgery or glaucoma surgery or complex posterior segment surgery we

116 2 mm Hg and 20% reduction without additional glaucoma surgery or devastating complication.

117 jects were excluded if they had had previous glaucoma surgery or laser and also if intraocular surger

118 he time of surgery vs 22% with no history of glaucoma surgery or medication use; HR, 4.1 [99% CI, 2.2

119 ter excluding participants with a history of glaucoma surgery or medication, refractive surgery, corn

120 below medicated baseline without additional glaucoma surgery or medications.

121 t reduced by 20%, IOP </=5 mm Hg, additional glaucoma surgery, or loss of light perception vision).

122 fter the first 6 weeks after surgery, repeat glaucoma surgery, or loss of light perception.

123 ns increased with more severe VF loss, prior glaucoma surgery, or younger age.

124 t the clinical relevance of such findings on glaucoma surgery outcomes remains unknown.

125 went cataract surgery and 79 (4.8%) received glaucoma surgery over the 2-year follow-up.

126 ouracil and mitomycin C, have revolutionized glaucoma surgery over the past decade.

127 e correlated; in a multivariate model, prior glaucoma surgery (P < 0.0001) and a prior rejection epis

128 igher risk of IOP elevation and the need for glaucoma surgery (P = .003, P < .001, and P < .001, resp

129 laucoma medications (P = .003) or to undergo glaucoma surgery (P = .016) than Roper-Hall grade I or I

130 e same period, the mean number of incisional glaucoma surgeries performed per surgeon doubled, and th

131 the same time, the proportion of incisional glaucoma surgery provided by high-volume glaucoma surgeo

132 about activities correlated with history of glaucoma surgery (r = 0.148; P = .023) and VF MD of the

133 OP] target of 6-18 mm Hg inclusive), de novo glaucoma surgery rates, mean IOP, mean glaucoma medicati

134 In addition, the sequencing of glaucoma surgery relative to penetrating keratoplasty af

135 ines from patients with and without previous glaucoma surgery, respectively.

136 the use of antifibrotic agents adjunctive to glaucoma surgery, reviews recently published studies tha

137 Despite the advent of many new devices for glaucoma surgery, scarring is the main cause of suboptim

138 Glaucoma surgery should be offered early to those with a

139 Recently introduced microincisional glaucoma surgeries that enhance conventional outflow off

140 issue with regard to coincident cataract and glaucoma surgery, that is, the indications for the proce

141 , long-term results of combined cataract and glaucoma surgery, the survival of filtration blebs after

142 cular pressure could lead to higher rates of glaucoma surgery to lower this pressure.

143 From glaucoma surgery to the management of various corneal di

144 e laser trabeculoplasty (SLT) and eventually glaucoma surgery (Trabectome) in 2 eyes for disease mana

145 thy attributable to overfiltration following glaucoma surgery (trabeculectomy with mitomycin C) were

146 e glaucoma patients without prior incisional glaucoma surgery undergoing phacoemulsification by a sin

147 medical therapy, without previous incisional glaucoma surgery underwent trabeculectomy (85 eyes) or c

148 ure at 1, 2, 3, and 4 years after additional glaucoma surgery was 0%, 43%, 43%, and 43%, respectively

149 Mean age +/- standard deviation at initial glaucoma surgery was 11.1 +/- 4.4 years with a follow-up

150 Follow-up (mean +/- SD) after additional glaucoma surgery was 28.0 +/- 16.0 months in the tube gr

151 Previous glaucoma surgery was associated with a significantly inc

152 us associated with binocular diplopia due to glaucoma surgery was hypertropia (10/11 GDD cases, 2/2 t

153 Additional glaucoma surgery was needed more frequently after trabec

154 and 15.0% (95% CI, 11.8-19.1) respectively; glaucoma surgery was performed in 2.4% of eyes (95% CI,

155 Additional glaucoma surgery was performed in 8 patients in the tube

156 ason for failure in both groups, and de novo glaucoma surgery was required in 16% of the Ahmed group

157 diplopia and binocular diplopia unrelated to glaucoma surgery was similar among medical and surgical

158 lure of medical treatment in controlling the glaucoma, surgery was offered to the patient.

159 Patients requiring further glaucoma surgery were considered failures.

160 at baseline and candidates for conventional glaucoma surgery were enrolled.

161 No differences in need for glaucoma surgery were noted among those with OAG who wer

162 glaucoma medication, or not having undergone glaucoma surgery) were identified.

163 dvanced disease and who had either undergone glaucoma surgery, were receiving medical treatment, or h

164 itomycin-C trabeculectomy and nonpenetrating glaucoma surgery, when the most recent modification has

165 Penetrating glaucoma surgery will continue to evolve.

166 of patients with conjunctival fibrosis after glaucoma surgery with candidate gene expression tissue b

167 Combining glaucoma surgery with minimal invasive phacoemulsificati

168 cally reviews recent advances in penetrating glaucoma surgery with particular attention paid to two n

169 scriptions and had no cataract or additional glaucoma surgery within 2 years after LPIs.

170 roportion of enrollees requiring cataract or glaucoma surgery within 2 years after the LPIs were dete

171 ture as it pertains to combined cataract and glaucoma surgery within the 1-year scanning period.